Q.30 Match the recombinant DNA products in Group I with its application in
Group II
Group I Group II
P) Tissue plasminogen activator 1) Emergency treatment of heart
attack
Q) Erythropoietin 2) Treatment of anemia
R) Superoxide dismutase 3) Prevents tissue damage
S) Interferon 4) Stimulates cells to inhibit viral
replication
(A) P–1, Q–2, R–3, S–4
(B) P–1, Q–3, R–4, S–2
(C) P–3, Q–1, R–4, S–2
(D) P–4, Q–3, R–1, S–2
Option (A) P-1, Q-2, R-3, S-4 is the correct match for this CSIR NET Life Sciences question on recombinant DNA products and their therapeutic applications.
Tissue plasminogen activator (tPA) dissolves blood clots during heart attacks, erythropoietin treats anemia by boosting red blood cell production, superoxide dismutase protects tissues from oxidative damage, and interferon inhibits viral replication.
Introduction
Recombinant DNA products applications matching questions test core biotechnology knowledge for CSIR NET Life Sciences aspirants, linking proteins like tissue plasminogen activator and erythropoietin to therapies such as heart attack treatment and anemia management. These matches highlight rDNA technology’s role in producing human proteins via bacterial or mammalian expression systems, revolutionizing medicine since the 1980s.
Correct Matches Explained
Each Group I product pairs precisely with its Group II application based on established therapeutic uses.
| Product (Group I) | Application (Group II) | Mechanism |
|---|---|---|
| P) Tissue plasminogen activator | 1) Emergency treatment of heart attack | Converts plasminogen to plasmin, dissolving coronary clots in myocardial infarction. |
| Q) Erythropoietin | 2) Treatment of anemia | Stimulates erythropoiesis in bone marrow for chronic kidney disease or chemotherapy-induced anemia. |
| R) Superoxide dismutase | 3) Prevents tissue damage | Dismutates superoxide radicals, reducing oxidative stress in ischemia-reperfusion injury. |
| S) Interferon | 4) Stimulates cells to inhibit viral replication | Induces antiviral state via JAK-STAT pathway, blocking viral protein synthesis. |
This table reflects standard pairings from recombinant pharmacology.
Option Analysis
Option (A) P-1, Q-2, R-3, S-4: Correct. Matches tPA to thrombolysis in acute MI, erythropoietin to anemia, SOD to antioxidant protection, and interferon to antiviral action—aligning with clinical approvals.
Option (B) P-1, Q-3, R-4, S-2: Incorrect. Erythropoietin does not prevent tissue damage (SOD’s role), SOD lacks viral inhibition, and interferon is not for anemia.
Option (C) P-3, Q-1, R-4, S-2: Incorrect. tPA causes fibrinolysis, not antioxidant protection; erythropoietin treats anemia, not heart attacks.
Option (D) P-4, Q-3, R-1, S-2: Incorrect. tPA is thrombolytic, not antiviral; SOD protects from ROS, not heart attack clots.
